An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers
Open Access
- 31 May 1990
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 61 (6) , 821-827
- https://doi.org/10.1038/bjc.1990.184
Abstract
Prognostic information is essential for the evaluation, judgement and optimal treatment of patients with squamous cell cancers (SCCs) of the upper aerodigestive tract. Using immunohistochemical and flow cytometric techniques, we have studied the significance of cellular expression of the Ki-67 antigen, epidermal growth factor receptor (EGFR), the transferrin receptor (TFR) and DNA ploidy status in a prospective analysis of patients with SCCs of the head and neck region. All 42 fresh tumour samples (five well differentiated; 28 moderately differentiated; nine poorly differentiated) expressed both EGFR and TFR to varying degrees. Receptor expression was most marked on the peripheral invading margin of cancer cell islands although staining was also demonstrated in a random fashion within cellular islands and consistently along the basal cell layer of overlying stratified squamous epithelium. The percentage of cancer cells that reacted with the Ki-67 monoclonal antibody was assessed as low (< 10%) in 15 samples (35.8%), intermediate (10-30%) in 19 samples (45.2%) and high (>30%) in eight samples (19.0%). Eleven of 15 samples (73%) with a low percentage reactivity were DNA diploid, whereas seven of eight samples (87.5%) with a high percentage reactivity were DNA aneuploid. Poorly differentiated SCCs were significantly more often aneuploid than were either moderately or well differentiated tumours. Our results suggest that EGFR and TFR are widely distributed on SCCs, especially on proliferating cells at the invading tumour margin. In addition, there is a close spatial correlation between cells expressing EGFR, TFR and those expressing the Ki-67 antigen. Tumours in which the staining intensity for both EGFR and TFR was intense invariably expressed the Ki-67 antigen in a high proportion of cells. Further patient follow-up will be important in determining whether intense EGFR and TFR staining, combined with a high percentage reactivity with Ki-67 antibody and DNA aneuploidy, will ultimately define a subset of head an neck cancer patients with a poor clinical outcome.Keywords
This publication has 46 references indexed in Scilit:
- K-67 Immunoreactivity in Breast Carcinomas in Relation to Transferrin Receptor Expression, Estrogen Receptor Status and Morphological CriteriaOncology, 1989
- Ki‐67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlationsThe Journal of Pathology, 1988
- The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival materialEuropean Journal of Cancer and Clinical Oncology, 1987
- Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.Journal of Clinical Pathology, 1986
- Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line.Journal of Clinical Investigation, 1985
- What Does Epidermal Growth Factor Do and How Does It Do It?Journal of Investigative Dermatology, 1985
- Human squamous cell lung cancers express increased epidermal growth factor receptors.Journal of Clinical Investigation, 1984
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cellsInternational Journal of Cancer, 1981